Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TERBINAFINE HCL

All products: general benefit

PMS-Terbinafine · DIN 02294273 · 250mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Terbinafine · DIN 02294273 Manufacturer: Pharmascience Inc.; listing date 2009-09-30 Health Canada: Marketed since 2009-06-19 · brand PMS-TERBINAFINE · ATC D01BA02 TERBINAFINE · form Tablet · route Oral · ingredients TERBINAFINE (TERBINAFINE HYDROCHLORIDE) 250 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Terbinafine: Formulary list price $0.7714/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7714 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77963 · Verify on the e-Formulary ↗ (DIN 02294273)

Source record
DIN 02294273: PMS-Terbinafine Raw flags: sec3=Y Item: 081204016; group id 16; item number 0021; lccId None; manufacturer id PMS Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.7714; ministry $0.7714 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02294273 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77963
Interchangeable products
Apo-Terbinafine · DIN 02239893 · $0.7714 Auro-Terbinafine · DIN 02320134 · $0.7714 Co Terbinafine · DIN 02254727 · $0.7714 Lamisil · DIN 02031116 · not recorded Terbinafine · DIN 02353121 · $0.7714 Terbinafine · DIN 02385279 · $0.7714 Teva-Terbinafine · DIN 02240346 · $0.7714
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:12:04 Antifungals) and how they are covered

Matched class: 08:12:04 Antifungals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMPHOTERICIN B Some products covered without a code (check the product listing): FLUCONAZOLE, ITRACONAZOLE, KETOCONAZOLE, NYSTATIN 08:12:04 Antifungals

AMPHOTERICIN B

· 1 products · General benefit · strengths: · Inj Pd-50mg Pk

FLUCONAZOLE

· 17 products · Limited Use, codes 528 (1), Listed, not a benefit (2), General benefit (14) · strengths: 10mg/mL, 50mg, 100mg · O/L, Tab

ITRACONAZOLE

· 5 products · General benefit (2), Listed, not a benefit (1), Limited Use, codes 570 (2) · strengths: 100mg, 10mg/mL · Cap, Oral Sol

KETOCONAZOLE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 200mg · Tab

NYSTATIN

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 100000U/mL · O/L

VORICONAZOLE

· 6 products · Limited Use, codes 399 · strengths: 50mg, 200mg · Tab

CASPOFUNGIN ACETATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial · Inj-Vial Pk

MICAFUNGIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial, 100mg/Vial · Inj Pd-10mL Vial Pk

POSACONAZOLE

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 40mg/mL · DR Tab, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:04
Full class listing Related classes: 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS LAMISIL® (terbinafine hydrochloride) is indicated for:  the treatment of fungal infections of the skin and nails caused by dermatophytes such as Trichophyton (e.g. T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis, Epidermophyton floccosum and yeasts of the genus Candida (eg. C. albicans), as well as Malassezia furfur. LAMISIL tablets:  the treatment of onychomycosis (fungal infection of the nail) caused by dermatophyte fungi. o Prior to initiating treatment with LAMISIL® tablets, appropriate nail or skin specimens should be obtained for laboratory testing (KOH preparation, fungal culture, or nail biopsy) in order to confirm the diagnosis of onychomycosis or dermatomycosis.  may be considered for the treatment of severe tineal skin infections (tinea corporis, tinea cruris and tinea pedis) which have been unresponsive to topical treatment. Note: LAMISIL tablets are not effective in pityriasis versicolor (also known as Tinea versicolor). LAMISIL cream and spray:  Cream o the treatment of fungal infections of the skin caused by dermatophytes such as tric… https://pdf.hres.ca/dpd_pm/00067056.PDF PM date: December 31, 1993 Source product: LAMISIL; DIN 02031094; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.